<DOC>
	<DOCNO>NCT00064454</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy drug OPC-6535 compare placebo patient active Ulcerative Colitis . Depending response , participant offer investigational medication one year study 's completion select site .</brief_summary>
	<brief_title>FACTS II : A Study Test Safety Effectiveness New Medication Treatment Active Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Male female subject , 1880 year age , inclusive , provide write informed consent prior studyrelated procedure , opinion Investigator , likely comply requirement study Subjects establish diagnosis active ulcerative colitis , relapse within 12 week screen . All subject must diagnosis ulcerative colitis establish colonoscopy* prior enter study . ( Newly diagnose patient also eligible . ) * Colonoscopy may substitute flexible sigmoidoscopy Screening inclusion criterion meet . Colonic involvement ulcerative colitis beyond 15 cm anal verge . Subjects active disease , define DAI score 7 11 , inclusive , Screening/Baseline Visit . A score ≥2 rectal bleed score ≥ 0 flexible sigmoidoscopy Screening/Baseline Visit , base DAI criterion . Subjects stable dose 5ASA least 14 day prior Screening/Baseline Visit OR subject receive 5ASA least 14 day . Subjects surgically sterilize prepared agree practice doublebarrier form birth control Screening/Baseline Visit 30 ( female ) 90 ( male ) day , respectively , last dose study medication . Females 12 month postmenopausal also eligible participate study . Subjects severe disease , define DAI 12 Screening/Baseline Visit , and/or subject Investigator deem likely require immunosuppressant therapy include corticosteroid and/or hospitalization period study . Subjects clinically significant disease ( ) , opinion Investigator , could compromise subject 's involvement study and/or interfere absorption study drug overall interpretation data . Subjects major gastrointestinal surgery include , limited , colostomy , ileostomy previous colonic surgery appendectomy . Subjects use oral corticosteroid ( include oral budesonide ) within 30 day , topical intrarectal agent ( corticosteroid 5ASA enema , suppository , foam ) within 7 day Screening/Baseline . ( Topical dermatological corticosteroid exclude ) . Subjects use immunosuppressant include , limited : azathioprine , 6mercaptopurine , methotrexate , within 28 day IL10 , IL11 , FK506 [ tacrolimus ] , mycophenolate , cyclosporine , antiTNFα monoclonal antibody medication within 60 day Screening/Baseline . Subjects history active malignancy within 5 year ( surgicallytreated basal cell , squamous cell , nonmelanoma situ cervical carcinoma permissible ) , intraabdominal abscess , toxic megacolon , clinical instability result cause . Subjects know suspected history sclerosing cholangitis . Subjects know suspected history clinically relevant cardiac disease . Subjects positive stool culture enteric pathogen , pathogenic ovum parasite , positive EIA subsequently confirm positive cytotoxin assay C. difficile toxin . ( Results enteric pathogen , pathogenic ovum parasite , C. difficile toxin , may pending time randomization study drug initiation . ) Subjects partial bowel obstruction , document proximal small bowel dilation Screening/Baseline . Additional exclusion criterion apply . Please see study Web site additional information .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Ulcerative Colitis</keyword>
</DOC>